Adult Growth Hormone Deficiency, Chronic Kidney Disease, Chronic Renal Insufficiency, Foetal Growth Problem, Genetic Disorder, Growth Hormone Deficiency in Children, Growth Hormone Disorder, Noonan Syndrome, Small for Gestational Age, Turner Syndrome
Conditions
Brief summary
This observational study is conducted globally. The aim of the study is to investigate the effectiveness and safety of real-life treatment with Norditropin®. The study population will consist of children and adults who are on treatment with Norditropin® in accordance with normal clinical practice.
Interventions
DRUGsomatropin
The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with adults.
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Judged by the physician as per the Norditropin® label
Exclusion criteria
* Judged by the physician as per the Norditropin® label
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effect of Norditropin® treatment on height gain (change in height) in children | Study outcomes (study endpoints) will be analysed and reported on annual basis. The mean follow up period for study outcomes is expected to be 5 years in accordance with defined duration of the study. |
| Effect of Norditropin® treatment on body weight and body composition in adults | Study outcomes (study endpoints) will be analysed and reported on annual basis. The mean follow up period for study outcomes is expected to be 5 years in accordance with defined duration of the study. |
Secondary
| Measure | Time frame |
|---|---|
| Effect of Norditropin® treatment body weight, blood biochemistry, bone age, the endocrine system and pubertal development in children | Study outcomes (study endpoints) will be analysed and reported on annual basis. The mean follow up period for study outcomes is expected to be 5 years in accordance with defined duration of the study. |
| Effect of Norditropin® treatment on quality of life, blood biochemistry and the endocrine system in adults | Study outcomes (study endpoints) will be analysed and reported on annual basis. The mean follow up period for study outcomes is expected to be 5 years in accordance with defined duration of the study. |
Countries
Argentina, Belgium, Czechia, Denmark, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Lithuania, Luxembourg, Netherlands, Norway, Russia, Saudi Arabia, Serbia, Slovenia, Spain, Sweden, Switzerland, United Kingdom
Outcome results
None listed